top of page

Probiotic Blend vs Synbiotic Blend: What's the Difference?

4 days ago
30 min read

The growing scientific interest in the human gut microbiome has created opportunities for the development of probiotic and synbiotic products across the nutraceutical, dietary supplement, functional food and nutrition industries. Manufacturers are increasingly investigating combinations of microorganisms and functional substrates to develop formulations with defined technical characteristics and scientifically supportable benefits.

Within this evolving market, two terms frequently appear in product development discussions: probiotic blend and synbiotic blend.

Although both formulation types involve microorganisms and may be developed for similar product categories, they are not scientifically interchangeable.

A probiotic blend typically combines two or more selected probiotic strains in a single formulation. A synbiotic, by contrast, is defined as a mixture comprising live microorganisms and substrate or substrates that are selectively utilized by host microorganisms and that confer a health benefit on the host. This definition was established by an international expert panel convened by the International Scientific Association for Probiotics and Prebiotics (ISAPP) [1].

The distinction has practical implications for ingredient selection, product design, manufacturing, stability testing, scientific substantiation and regulatory compliance.

For example, a capsule containing selected strains of Lactobacillus and Bifidobacterium may be developed as a multi-strain probiotic blend. If a suitable prebiotic substrate is added, the resulting product may be a candidate for synbiotic development. However, simply combining probiotics with inulin, fructooligosaccharides (FOS) or another ingredient commonly described as a prebiotic does not automatically establish that the finished product meets the scientific definition of a synbiotic.

The ISAPP consensus statement identifies two categories of synbiotics: complementary synbiotics and synergistic synbiotics. These categories differ in how the microorganisms and substrates are selected and how their relationship is substantiated [1].

Understanding these distinctions helps manufacturers move beyond ingredient combinations towards formulations supported by an appropriate scientific rationale.

This article examines the differences between probiotic and synbiotic blends, their biological principles, commonly used ingredients, formulation requirements, manufacturing considerations, clinical research and regulatory frameworks. It also explains how supplement brands and B2B ingredient buyers can evaluate the suitability of each formulation approach.

Lactobacillus plantarum powder used in multi-strain probiotic blends
A probiotic blend combines two or more selected strains, such as Lactobacillus plantarum, in one formula.

What Is a Probiotic Blend?

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.

This definition is widely used in scientific research and provides a foundation for evaluating probiotic ingredients. It highlights three important requirements:

  • The microorganisms must be alive when administered.

  • They must be provided in an adequate amount for their intended use.

  • A health benefit must be demonstrated for the relevant microorganism and conditions of use.

Not every microorganism used in food fermentation qualifies as a probiotic. Similarly, the presence of live bacteria in a dietary supplement does not, by itself, establish that the product provides a particular health benefit.

Probiotic research includes microorganisms from several bacterial genera, including Lactobacillus, Bifidobacterium and Bacillus, as well as certain yeasts. Their properties vary according to the species and, importantly, the individual strain.

The internationally recognized consensus definition and appropriate use of the term probiotic are discussed in the ISAPP statement published in Nature Reviews Gastroenterology & Hepatology [2].

What does the term probiotic blend mean?

A probiotic blend is a formulation containing multiple probiotic strains or microorganisms.

Depending on the product design, it may contain:

  • Multiple strains belonging to the same species.

  • Different species within one bacterial genus.

  • Strains from different bacterial genera.

  • Selected bacterial probiotics combined with a probiotic yeast.

  • Several microorganisms selected for a defined formulation objective.

For example, a hypothetical formulation might combine selected strains of Lactobacillus, Bifidobacterium and Bacillus.

The purpose of such a combination is not simply to increase the number of microorganisms in the product. Rather, the strains should be selected according to their relevant properties, supporting evidence, compatibility and intended application.

Different strains may have different oxygen tolerances, moisture sensitivities, growth requirements and temperature stability. These differences influence both formulation design and the ability to maintain product quality during storage.

Consequently, a multi-strain probiotic blend should be treated as a deliberately engineered formulation rather than a random mixture of microorganisms.

Why do manufacturers develop multi-strain probiotic blends?

Manufacturers may develop multi-strain products for several reasons.

  • Strain diversity: Different strains may possess distinct biological and technological characteristics.

  • Formulation flexibility: Multiple strains can be combined in suitable capsules, powders, sachets, tablets and other delivery formats.

  • Product differentiation: A well-characterized combination may help a supplement brand develop a product with a defined technical identity.

  • Application-specific development: The selected strains can be evaluated according to the intended product, target population and available evidence.

  • Manufacturing requirements: A blend can be designed around potency specifications, raw-material availability, processing conditions and shelf-life targets.

However, combining several strains does not automatically produce a greater health benefit than using one strain. The value of a formulation depends on the characteristics of the selected microorganisms and the evidence supporting the final product.

Single-strain probiotics versus multi-strain probiotic blends

A single-strain probiotic contains one defined strain, whereas a multi-strain probiotic combines two or more.

Parameter

Single-strain probiotic

Multi-strain probiotic blend

Composition

One defined strain

Two or more strains

Formulation complexity

Generally lower

May be higher

Compatibility assessment

Focuses on the strain and other ingredients

Includes compatibility among strains

Potency assessment

Establishes the viable count of the selected strain

Requires a suitable strategy for assessing the combined formulation and relevant strains

Stability

Depends on the strain and product

Depends on each strain and their behaviour in the combined formulation

Scientific substantiation

Evidence should relate to the strain and intended use

Evidence should support the relevant combination and intended use

Manufacturing

Requires appropriate controls for the selected strain

May require additional controls for blending and strain-specific quality

Product development

Focuses on a defined microorganism

Focuses on a scientifically justified combination

A multi-strain formulation may be suitable when there is a clear reason to combine the microorganisms. A single-strain product may be more appropriate when a particular strain has strong relevant evidence or offers practical manufacturing advantages.

The number of strains should therefore be a consequence of the formulation objective, not the principal measure of product quality.

Why strain identification matters

Strain-level identification is essential in probiotic product development.

Two strains belonging to the same species can differ in their physiological characteristics, substrate utilization, processing tolerance and studied biological effects. Evidence obtained for one strain cannot automatically be attributed to every member of its species.

A suitable technical dossier should address:

  • Current taxonomic identification.

  • A unique strain designation.

  • Strain traceability and provenance.

  • Relevant safety information.

  • Available scientific evidence.

  • Viable-cell potency specifications.

  • Storage and handling requirements.

  • Compatibility information, where available.

For B2B buyers, these details help establish whether an ingredient is suitable for a particular formulation and whether the supporting documentation is adequate.

For manufacturers, reliable strain identification also supports batch traceability, supplier qualification and consistency between the research ingredient and the commercial material.

Bifidobacterium longum probiotic powder for synbiotic formulations
A synbiotic pairs live microorganisms with substrates they or resident microbes selectively use.

What Is a Synbiotic Blend?

The scientific definition of a synbiotic

A synbiotic is a mixture comprising live microorganisms and substrate or substrates that are selectively utilized by host microorganisms and that confer a health benefit on the host [1].

This definition is more precise than the simplified commercial description of a synbiotic as a combination of a probiotic and a prebiotic.

It focuses on the biological function of the formulation and the benefit demonstrated for the intended host.

Three elements are central:

  • Live microorganisms: The formulation contains live microorganisms.

  • Selective substrate utilization: Relevant host microorganisms selectively utilize the substrate.

  • Health benefit: The formulation confers a demonstrated benefit on the intended host.

The substrate may target microorganisms already present in the host's microbial community or microorganisms administered as part of the formulation.

This distinction enables synbiotic development to include different approaches to combining microorganisms and substrates, rather than limiting innovation to one particular ingredient combination.

Understanding prebiotics

A prebiotic is a substrate that is selectively utilized by host microorganisms and confers a health benefit.

Some prebiotics are fermentable carbohydrates that can be used by selected microorganisms in the gastrointestinal tract. Depending on the substrate and the microorganisms present, their utilization may influence microbial activity and the production of metabolites.

Ingredients investigated for prebiotic applications include:

  • Inulin.

  • Fructooligosaccharides (FOS).

  • Galactooligosaccharides (GOS).

  • Certain resistant starches.

  • Other substrates investigated for selective microbial utilization.

These ingredients are not interchangeable. They differ in chemical structure, fermentability, physical characteristics, microbial utilization and potential gastrointestinal effects.

The scientific definition of prebiotics and the evidence required to substantiate their effects are discussed in the ISAPP consensus statement published in Nature Reviews Gastroenterology & Hepatology [3].

For formulation scientists, the key question is not simply whether an ingredient is commonly marketed as a prebiotic. It is whether the ingredient is appropriate for the intended formulation and whether its use is supported by relevant evidence.

Why combine probiotics and prebiotics?

A synbiotic formulation brings together live microorganisms and a selectively utilized substrate.

Depending on the formulation, the microorganisms may contribute a demonstrated health benefit, while the substrate may influence resident microbial populations.

Alternatively, the formulation may be designed so that the substrate is selectively utilized by the co-administered microorganism.

These approaches form the basis of complementary and synergistic synbiotics.

The intended benefit must be established for the relevant formulation. Evidence that an individual probiotic has a health benefit, or that a prebiotic influences microbial activity, does not automatically demonstrate that every combination of the two will be effective.

This is a fundamental principle for manufacturers developing scientifically substantiated products.

Complementary synbiotics

A complementary synbiotic combines a probiotic and a prebiotic that contribute to a health benefit without necessarily being designed to function cooperatively.

In this formulation approach, the probiotic and prebiotic may act through different biological pathways.

For example, a hypothetical product could combine:

  • A characterized probiotic strain with relevant supporting evidence.

  • A suitable prebiotic substrate with evidence of selective utilization and a relevant health benefit.

The formulation may be developed as a complementary synbiotic if the components meet the applicable criteria and the combined product is shown to confer a health benefit [1].

The probiotic does not necessarily need to utilize the accompanying prebiotic. The substrate may instead target relevant microorganisms already present in the host.

However, the final combination still requires appropriate substantiation. Evidence for each component separately does not automatically establish the efficacy of every possible combination.

Synergistic synbiotics

A synergistic synbiotic is designed so that the substrate is selectively utilized by the co-administered live microorganism or microorganisms.

The formulation strategy aims to establish a meaningful functional relationship between the microorganism and the substrate.

For example, researchers may identify a probiotic strain capable of utilizing a particular carbohydrate and investigate whether that substrate supports the microorganism's activity under relevant conditions.

A development programme may involve:

  • Screening candidate strains for substrate utilization.

  • Characterizing growth or metabolic responses under controlled conditions.

  • Assessing compatibility between the selected microorganism and substrate.

  • Evaluating stability in the finished product.

  • Investigating relevant biological outcomes.

  • Conducting appropriately designed studies in the intended host.

The selective-utilization relationship and health benefit must be demonstrated rather than assumed from the ingredient list. The ISAPP consensus statement discusses the scientific evidence needed to substantiate synergistic synbiotics [1].

Complementary versus synergistic synbiotics

The difference is important for formulation design, research and product communication.

Feature

Complementary synbiotic

Synergistic synbiotic

Formulation concept

Combines a probiotic and prebiotic that contribute to a health benefit

Combines a live microorganism with a substrate selected for its utilization by that microorganism

Intended relationship

Components do not need to function cooperatively

Components are deliberately designed to function together

Substrate utilization

Relevant utilization by resident microorganisms

Selective utilization by the co-administered microorganism must be demonstrated

Research objective

Establish component suitability and health benefit of the combination

Establish the relevant microorganism–substrate relationship and health benefit

Development complexity

Depends on the ingredients and intended application

May require additional studies of selective utilization

Evidence

Must support the formulation and intended use

Must support the proposed functional relationship and health benefit

Neither category is automatically superior. The appropriate approach depends on the intended product, the available evidence and the feasibility of establishing the required scientific properties.

Probiotic Blend vs Synbiotic Blend: A Detailed Comparison

The principal difference between the two formulations is the role of the substrate and the scientific evidence supporting the complete product.

A probiotic blend focuses on the selection and combination of live microorganisms. A synbiotic formulation includes live microorganisms and selectively utilized substrates that together satisfy the relevant criteria for a health benefit.

Comparative table

Comparison parameter

Probiotic blend

Synbiotic blend

Primary composition

Multiple probiotic strains

Live microorganisms and selectively utilized substrates

Number of strains

Usually two or more in a blend

One or more, depending on the formulation

Prebiotic substrate

Not essential

Commonly included in commercial formulations

Main development objective

Combine suitable probiotic strains for a defined purpose

Develop a scientifically substantiated microorganism–substrate formulation

Ingredient selection

Based on strain identity, evidence and technical compatibility

Based on microbial characteristics, substrate properties and the intended relationship

Biological rationale

Depends on the selected strains

Depends on the microorganisms, substrate and formulation category

Compatibility testing

Assesses strain interactions and ingredient compatibility

Assesses strain interactions, substrate compatibility and other relevant properties

Quality control

Identity, viable count, purity and finished-product quality

Probiotic quality, substrate specifications and finished-product quality

Stability

Depends on strains, dosage form, packaging and storage

Also considers substrate properties and their influence on the complete formulation

Clinical evidence

Should support the relevant formulation and intended benefit

Should support the synbiotic formulation and intended benefit

Manufacturing complexity

Depends on the number and properties of strains

May require additional studies of substrate utilization and combined-product performance

Commercial applications

Capsules, sachets, powders and other suitable formats

Capsules, sachets, powders, selected foods and other suitable formats

Regulatory considerations

Product classification, safety and permitted claims

The same considerations, with additional attention to synbiotic substantiation where relevant

Is every probiotic and prebiotic combination a synbiotic?

No. This is one of the most important points in synbiotic science.

A product may contain a probiotic and an ingredient commonly described as a prebiotic without necessarily satisfying the scientific requirements for a synbiotic.

Under the ISAPP framework, a complementary synbiotic must meet the applicable criteria for the probiotic and prebiotic components, and the combined formulation must demonstrate a health benefit. A synergistic synbiotic requires evidence of selective utilization of the substrate by the co-administered microorganism and evidence of a health benefit [1].

Manufacturers should therefore distinguish among three situations:

  • Ingredient combination: A product contains probiotics and a prebiotic ingredient.

  • Formulation rationale: The manufacturer has a scientific and technical basis for selecting the ingredients.

  • Synbiotic substantiation: The formulation meets the scientific criteria for its intended synbiotic category and has supporting evidence for the intended benefit.

These are related but different concepts.

For B2B manufacturers, maintaining this distinction can help establish credible product descriptions and reduce the risk of making unsupported claims.

Is a synbiotic always more effective than a probiotic blend?

No. Current evidence does not establish that synbiotic formulations are universally superior to probiotic blends.

The effectiveness of a formulation depends on the strains, substrate, dose, target population, duration of use, dosage form and outcome being evaluated.

A probiotic blend may be appropriate when the selected strains have relevant evidence for the intended application. A synbiotic may be appropriate when the microorganism–substrate combination has a clear scientific rationale and supporting evidence.

Comparisons should therefore focus on specific formulations rather than assuming that one category is inherently superior.

What does the addition of a prebiotic change?

Adding a substrate can affect several aspects of product development.

It changes the ingredient composition, may alter the powder's physical properties and can influence the moisture characteristics of the formulation. Depending on the substrate, it may also affect taste, solubility, gastrointestinal tolerance and the amount of material needed per serving.

The addition of a substrate also creates additional scientific questions. These include whether the substrate is selectively utilized by relevant microorganisms and whether the combined formulation provides the intended health benefit.

A formulation scientist should evaluate these questions alongside the usual requirements for probiotic viability and stability.

Biological Mechanisms: How Probiotic and Synbiotic Blends May Work

Understanding the underlying biology helps explain why the two formulation categories differ.

However, proposed mechanisms must be interpreted carefully. A mechanism observed in laboratory research does not automatically demonstrate a clinical benefit in humans.

Probiotic interactions with the intestinal environment

Probiotic microorganisms may interact with the gastrointestinal environment through several mechanisms, depending on the strain and application.

These mechanisms can include:

  • Competition with other microorganisms for nutrients.

  • Interactions with intestinal epithelial surfaces.

  • Production of organic acids and other metabolites.

  • Changes in microbial activity.

  • Interactions with host signalling pathways.

  • Effects on the local microbial environment.

The relevance of each mechanism depends on the microorganism, the formulation and the conditions under which it is administered.

For example, a strain's ability to produce a particular metabolite in laboratory culture does not guarantee that the same quantity will be produced in the human gastrointestinal tract.

Similarly, evidence that a strain influences a biological pathway does not necessarily establish that a finished supplement improves a clinically meaningful outcome.

Manufacturers should distinguish between mechanistic evidence, clinical evidence and permitted commercial claims.

The role of prebiotic substrates

Prebiotic substrates can be selectively utilized by microorganisms in the host's microbial ecosystem.

Their utilization may influence microbial activity and fermentation. Some fermentable substrates can contribute to the production of short-chain fatty acids, including acetate, propionate and butyrate.

These metabolites have been investigated for their roles in intestinal physiology, microbial ecology and host signalling.

However, the resulting metabolic profile depends on the substrate, the microorganisms present and the surrounding environment.

A substrate does not guarantee a particular metabolite concentration in every individual. Differences in baseline microbiota, diet, gastrointestinal transit and other factors can influence the response.

The ISAPP consensus on prebiotics discusses the relationship between selective utilization and health benefit [3].

How complementary synbiotics may function

In a complementary synbiotic, the probiotic and prebiotic components may contribute to a health benefit through different pathways.

The probiotic component is selected according to its relevant properties and evidence. The prebiotic component is selected according to its selective utilization and health-related characteristics.

The components do not have to demonstrate that the administered probiotic specifically utilizes the substrate.

Nevertheless, the finished combination must be supported by suitable evidence. It is not sufficient to assume that two individually promising ingredients will necessarily produce the intended benefit when combined.

How synergistic synbiotics may function

A synergistic synbiotic is deliberately designed around the relationship between a live microorganism and a substrate that it selectively utilizes.

The development strategy may investigate whether the substrate supports the microorganism's activity and whether that relationship contributes to the intended health outcome.

For example, a research team might screen several candidate substrates to identify one that a selected strain can utilize under relevant conditions. The team could then investigate whether the combination produces a reproducible biological response and whether that response is associated with a health benefit.

This requires more than demonstrating growth in a laboratory medium. The relationship must be relevant to the formulation, and the health benefit must be established in the intended host.

Why individual responses differ

The human gut microbiome varies among individuals.

Diet, age, baseline microbial composition, medication use, health status and gastrointestinal physiology can influence the environment in which a probiotic or synbiotic operates.

A substrate that is readily utilized by one microbial community may be used differently by another. Similarly, a strain may survive or function differently under different conditions.

These variations help explain why a formulation may not produce identical results in every consumer.

They also reinforce the importance of selecting an appropriate target population and evaluating clinical evidence in a population relevant to the intended use.

Lactobacillus casei probiotic ingredient selection
Ingredient selection starts with a clearly defined product objective.

Selecting Ingredients for Probiotic and Synbiotic Formulations

Ingredient selection should begin with a clearly defined product objective.

The number of strains or the desire to include multiple functional ingredients should not be the starting point.

Define the target application

Before selecting ingredients, manufacturers should establish the intended application and target population.

Potential product-development categories include:

  • General digestive wellness.

  • Products designed to support regularity.

  • Formulations for specific life stages.

  • Products intended for defined food or beverage matrices.

  • Formulations investigated for a specific outcome in clinical research.

These are product-development objectives, not automatic health claims. Each proposed benefit requires appropriate scientific substantiation and compliance with the relevant regulations.

A defined objective helps narrow the strain-selection process and determine whether a probiotic blend or synbiotic formulation is more suitable.

Selecting probiotic strains

Potential probiotic strains should be evaluated for identity, safety, viability, technological properties and evidence relevant to the intended application.

Important criteria include:

  • Strain identity: Is the strain adequately characterized and traceable?

  • Safety: Is there appropriate safety information for the intended population and conditions of use?

  • Scientific evidence: Is there relevant evidence for the proposed benefit?

  • Viability: Can the strain maintain the required viable count throughout shelf life?

  • Compatibility: Can it be combined with other strains and formulation ingredients?

  • Manufacturing feasibility: Can it be processed, blended and packaged consistently?

  • Supply reliability: Is the material available from a dependable source with appropriate quality documentation?

A strain that performs well in laboratory research may not be the best commercial choice if it cannot maintain adequate viability during storage or processing. See our guide on how to select probiotic strains for more detail.

Selecting a suitable prebiotic substrate

Prebiotic selection should consider the intended biological role and the characteristics of the finished product.

Key questions include:

  • Is there evidence of selective utilization by relevant microorganisms?

  • Is the substrate compatible with the selected strains?

  • Is the proposed amount appropriate for the intended use?

  • Could the ingredient cause bloating, gas or gastrointestinal discomfort?

  • Does it affect powder flow, dissolution, taste or texture?

  • Could it influence moisture stability?

  • Is it suitable for the intended dosage form?

  • Does it meet the regulatory requirements of the target market?

Inulin and FOS are examples of widely investigated prebiotic ingredients, but they are not automatically appropriate for every formulation.

The best substrate is not necessarily the one that produces the greatest growth in a laboratory medium. Its suitability depends on the intended application, the complete formulation and the available evidence.

Can multiple strains and prebiotics be combined?

Yes. A formulation can contain several probiotic strains and several substrates, provided the combination is safe, technically feasible and scientifically justified.

However, additional ingredients can increase the number of interactions that require evaluation.

A multi-strain formulation containing two substrates may require assessment of:

  • Individual strain viability.

  • Compatibility among the strains.

  • Relevant substrate utilization.

  • Moisture sensitivity.

  • Blending uniformity.

  • Powder flow and filling performance.

  • Finished-product stability.

  • Gastrointestinal tolerance at the intended intake.

  • Evidence supporting the combined formulation.

A more complex formula is not automatically better. A simpler formulation with clearly defined specifications may be easier to manufacture, validate and maintain throughout shelf life.

Bacillus coagulans probiotic powder manufacturing and stability
Viability, moisture, oxygen and packaging all need checking in the finished blend.

Manufacturing and Formulation Considerations

Probiotic and synbiotic blends require careful formulation because live microorganisms may be sensitive to processing conditions and storage environments.

The inclusion of a prebiotic can also change the physical properties of a powder or capsule blend. Synbiotic development should therefore evaluate the finished product rather than relying only on the individual ingredient specifications.

Viable-cell count and potency

Probiotic products are commonly specified in colony-forming units (CFU), a measure of viable microorganisms capable of forming colonies under the test conditions.

The declared quantity should be supported by an appropriate test method and a clearly defined specification.

For multi-strain products, manufacturers should determine whether the quality-control strategy can establish the viable count of each strain or otherwise verify the composition using a scientifically justified method.

This can be challenging when strains have similar growth characteristics or when the analytical methods cannot reliably distinguish them.

For synbiotic products, adding a substrate does not remove the need to verify probiotic viability.

The formulation should maintain the required viable count through the end of shelf life under the labelled storage conditions. Any manufacturing overage should be based on stability data and justified specifications.

Moisture and water activity

Moisture management is an important consideration in probiotic manufacturing.

Elevated moisture or water activity can affect microbial viability and may increase degradation during storage. The magnitude of the effect depends on the strains, ingredients, packaging and environmental conditions.

A synbiotic formulation containing moisture-sensitive or hygroscopic ingredients may require additional attention to moisture control.

Potential measures include:

  • Controlling environmental humidity during blending and packaging.

  • Selecting suitable ingredient grades.

  • Evaluating the moisture characteristics of the combined blend.

  • Choosing appropriate barrier packaging.

  • Establishing justified storage conditions.

  • Conducting stability studies under relevant conditions.

These measures should be selected according to the actual product rather than applied as a universal manufacturing recipe.

Oxygen and temperature

Some probiotic strains are more sensitive to oxygen or temperature than others.

The sensitivity of the individual strains should inform the choice of processing conditions, packaging system and storage requirements.

Manufacturers may need to assess:

  • Oxygen exposure during material handling.

  • Temperature during blending and filling.

  • The effects of transportation conditions.

  • Packaging compatibility.

  • Manufacturing delays.

  • Stability under anticipated distribution conditions.

The presence of a prebiotic does not guarantee that a probiotic will survive processing or storage. Any protective effect should be demonstrated for the actual formulation.

Dosage-form selection

The intended dosage form can influence formulation design.

  • Capsules: Suitable for many dry probiotic blends, subject to the required dose, fill weight, excipient compatibility and stability.

  • Powder sachets: Useful when the formulation requires a larger fill weight or a meaningful quantity of substrate.

  • Tablets: May require assessment of compression pressure, excipients, moisture and other processing variables that could affect viability.

  • Functional foods and beverages: May present additional challenges related to pH, water activity, heat treatment, oxygen exposure and storage conditions.

  • Chewables and specialised formats: Require assessment of taste, processing conditions and microbial stability.

The dosage form should be selected after evaluating the complete formula and intended market rather than choosing a format solely for commercial appearance.

Compatibility and stability testing

Compatibility testing should evaluate whether the selected strains and substrates can coexist in the finished product without unacceptable loss of quality.

A development programme may include:

  • Characterisation of the individual raw materials.

  • Preliminary compatibility assessment.

  • Pilot-scale blending and filling.

  • Initial microbiological and physicochemical testing.

  • Stability testing in the proposed packaging.

  • Evaluation under relevant storage conditions.

  • Confirmation of finished-product specifications.

  • Review of manufacturing consistency.

Delivery technologies such as microencapsulation have also been investigated for protecting probiotic microorganisms. Their suitability depends on the material, process and intended application.

The objective is to establish that the finished product consistently meets its specifications throughout the intended shelf life.

Packaging considerations

Packaging should protect the formulation from environmental conditions that could compromise quality.

Relevant factors may include:

  • Moisture-vapour transmission.

  • Oxygen exposure.

  • Light sensitivity.

  • Closure integrity.

  • Compatibility with the dosage form.

  • Storage and transport conditions.

Potential packaging options include suitable high-barrier sachets, blister packs, bottles and other validated systems.

The packaging decision should be supported by product-specific stability data.

For international distribution, manufacturers should also consider conditions encountered during shipping, customs clearance, warehousing and retail storage.

A product that performs well under controlled laboratory conditions may require additional evidence before its stability can be assured under more variable distribution conditions.

What Does Clinical Research Tell Us?

Clinical research is essential for understanding whether probiotic and synbiotic formulations produce meaningful health benefits.

The available literature includes laboratory experiments, mechanistic studies, randomised controlled trials, systematic reviews and meta-analyses. Each type of evidence answers different questions.

Laboratory findings may support a biological rationale, while clinical studies investigate outcomes in people. Neither the presence of a plausible mechanism nor the inclusion of ingredients studied separately establishes the efficacy of every finished product.

Why formulation-specific evidence matters

A clinical study evaluating one probiotic strain cannot automatically establish the efficacy of a different strain from the same species.

Likewise, evidence for a multi-strain probiotic blend does not automatically establish the effectiveness of a new synbiotic containing those strains and a prebiotic substrate.

Differences in strain identity, viable dose, substrate, dosage form, treatment duration and target population can influence outcomes.

When reviewing clinical evidence, manufacturers should ask:

  • Was the actual strain or formulation investigated?

  • Was the prebiotic ingredient and dose comparable?

  • Did the study evaluate the combined product?

  • Was the intended health outcome measured?

  • Was the study conducted in a relevant population?

  • Were the findings statistically and clinically meaningful?

  • Were safety and tolerability assessed?

These questions help distinguish general scientific plausibility from evidence that supports a particular formulation.

The ISAPP consensus on synbiotic research

The ISAPP consensus statement provides an important framework for evaluating synbiotic formulations. Published in Nature Reviews Gastroenterology & Hepatology, it defines complementary and synergistic synbiotics and discusses the evidence needed to substantiate their classification and health benefits [1].

For complementary synbiotics, evidence should establish the relevant properties of the probiotic and prebiotic components and demonstrate a benefit from the combination.

For synergistic synbiotics, research should additionally establish selective utilization of the substrate by the co-administered microorganism.

This framework is particularly useful for manufacturers seeking to move beyond simple ingredient combinations towards scientifically substantiated formulations.

Evidence concerning inflammatory biomarkers

Research has investigated whether probiotic, prebiotic and synbiotic interventions influence inflammatory biomarkers.

Some studies have reported changes in markers associated with inflammation, but the results vary according to the formulation, population, intervention period and outcome measured.

Several limitations must be considered when interpreting this literature:

  • The studies evaluate different formulations.

  • Populations and health conditions vary.

  • Doses and intervention periods are not uniform.

  • The results may differ across inflammatory markers.

  • Changes in biomarkers do not necessarily establish improvements in symptoms or long-term clinical outcomes.

Consequently, findings from an individual study should not be interpreted as proof that all synbiotic formulations reduce inflammation or that synbiotics consistently outperform probiotic blends.

For commercial product development, the relevant evidence must support the actual formulation and intended use.

Evidence from ulcerative colitis research

A network meta-analysis published in Clinical Nutrition in 2024 compared probiotic, prebiotic and synbiotic interventions used as adjunctive treatments in adults with mild-to-moderate ulcerative colitis.

The analysis included 20 trials involving 1,153 participants. Certain combinations of Lactobacillus and Bifidobacterium, with or without Streptococcus, were associated with improvements in clinical remission rates and disease activity scores compared with placebo. However, the authors rated the certainty of evidence for these findings as low and called for further research [5].

This example illustrates why findings should be interpreted within their clinical context.

The study examined specific interventions in a defined patient population. Its results cannot automatically be applied to healthy consumers, unrelated gastrointestinal conditions or commercial products with different strains and doses.

Furthermore, probiotic and synbiotic supplements should not be presented as replacements for established medical treatment of ulcerative colitis or other diagnosed conditions.

Evidence from other clinical applications

Probiotic and synbiotic interventions have also been investigated in metabolic health, gastrointestinal function and other areas.

However, results vary, and a finding associated with one formulation cannot be assumed to apply to another.

A systematic review may identify an overall pattern across several studies, but the interpretation depends on the similarity of the interventions, the quality of the trials and the certainty of the evidence.

For manufacturers, the practical lesson is to avoid broad claims based on isolated positive results.

A statistically significant change in a laboratory measurement does not necessarily indicate a clinically meaningful benefit. The magnitude of the effect, relevance to the target population, safety profile and consistency of the evidence must all be considered.

ClinicalTrials.gov as a research resource

ClinicalTrials.gov is a public registry that helps researchers and manufacturers identify registered clinical studies involving probiotics, prebiotics and synbiotics.

Useful search terms include synbiotic, probiotic and prebiotic, and the names of specific strains or substrates.

When evaluating a registered study, distinguish among:

  • Planned or recruiting trials.

  • Active trials that have not reported results.

  • Completed trials with results posted.

  • Published clinical studies.

  • Findings that have been independently replicated.

Registration does not establish that a product is effective. Similarly, a completed study without publicly available results should not be interpreted as evidence of a positive outcome.

What should a clinical trial of a synbiotic investigate?

A well-designed clinical study should address a clearly defined research question.

For a complementary synbiotic, investigators may assess whether the combined formulation provides the intended health benefit compared with an appropriate control.

For a synergistic synbiotic, the research should also address whether the substrate is selectively utilized by the administered microorganism and whether this relationship contributes to the intended outcome.

Depending on the research objective, a study may assess:

  • Relevant clinical symptoms or validated health outcomes.

  • Gastrointestinal tolerance and adverse events.

  • Microbial composition or activity.

  • Abundance or activity of the administered strain.

  • Relevant microbial metabolites.

  • Adherence and actual product intake.

  • Changes from baseline compared with an appropriate control.

The study should be adequately powered for its primary outcome, use appropriate statistical methods and report findings transparently.

Where the objective is to establish synergy, a design comparing the microorganism, substrate, combined formulation and control may be appropriate. The exact design should be determined by the scientific question and evidence requirements.

Regulatory Considerations for Probiotic and Synbiotic Products

Scientific formulation and regulatory compliance are closely connected.

A product may be technically feasible and scientifically interesting but still require changes to its labelling, claims or intended use before it can be marketed in a particular country.

Requirements differ across markets, making regulatory review an important part of product development.

European Union: EFSA and health claims

The European Food Safety Authority (EFSA) evaluates the scientific substantiation of health claims made about foods under the applicable European framework.

The assessment considers whether the evidence supports the claimed relationship between a food or constituent and a beneficial physiological effect. The conditions of use and the relevant population are also important [6].

For probiotic and synbiotic manufacturers, this means that claims should not be based solely on the presence of a probiotic strain, a prebiotic ingredient or a combination of the two.

A manufacturer planning to enter the European market should assess:

  • Whether the proposed claim is authorised for the intended use.

  • Whether the wording accurately reflects the permitted claim.

  • Whether the product meets the applicable conditions of use.

  • Whether the evidence applies to the product being marketed.

  • Whether the product's classification and labelling satisfy relevant requirements.

The regulatory treatment of terms such as probiotic and synbiotic may depend on the jurisdiction and context. Companies should not assume that a term used in scientific literature can automatically be used in every commercial communication [6].

Scientific substantiation and commercial communication

Marketing claims should reflect the evidence available for the product.

For example, a formulation containing a probiotic and inulin should not automatically be described as clinically proven to improve immunity, reduce inflammation or manage a metabolic disorder.

Such claims require appropriate substantiation and must comply with the applicable regulatory framework.

Product descriptions should distinguish among:

  • Ingredient identity and composition.

  • The intended formulation objective.

  • Mechanistic evidence from laboratory studies.

  • Evidence from human clinical trials.

  • Claims permitted in the target market.

This approach supports transparent scientific communication and reduces the risk of overstating a product's capabilities.

Documentation for international B2B buyers

International buyers frequently require detailed technical information before approving a probiotic or synbiotic ingredient.

A manufacturer should be prepared to provide documentation appropriate to the product and the customer's requirements.

Document or specification

Purpose

Technical data sheet

Describes ingredient identity, composition and technical characteristics

Certificate of Analysis (CoA)

Reports specified test results for the relevant batch

Strain identification records

Supports identity and traceability

Viable-count specification

Defines required probiotic potency

Microbiological quality results

Supports compliance with specified purity and safety criteria

Stability data

Supports proposed shelf life and storage conditions

Storage instructions

Describes conditions needed to maintain product quality

Allergen and ingredient information

Supports formulation review and labelling

Safety documentation

Provides information relevant to the intended use

Scientific references

Supports the technical rationale and relevant claims

Regulatory documentation

Supports market-specific evaluation

Packaging and shipping information

Helps buyers assess transport and storage requirements

The precise documentation required depends on the ingredient, finished product, destination market and customer specification.

For a synbiotic, documentation may also need to address the identity and quality of the substrate and the evidence supporting the proposed formulation.

Common Mistakes in Probiotic and Synbiotic Formulation

Even technically sophisticated formulations can encounter problems when development focuses on ingredient quantity rather than the scientific and manufacturing rationale.

Mistake 1: Assuming more strains mean better results

Increasing the number of probiotic strains does not automatically improve a formulation.

Every additional strain introduces potential compatibility, stability, sourcing and quality-control considerations.

Better approach: Select strains according to the intended application, relevant evidence and technical feasibility.

Mistake 2: Adding a prebiotic without evaluating its function

Adding inulin or FOS does not automatically establish a meaningful synbiotic relationship.

Better approach: Determine whether the formulation is intended to be complementary or synergistic and identify the evidence needed to support that approach.

Mistake 3: Assuming laboratory growth proves clinical efficacy

A strain's ability to grow in the presence of a substrate under laboratory conditions does not establish a health benefit in humans.

Better approach: Separate preliminary screening from clinical substantiation and use appropriate studies to establish the intended benefit.

Mistake 4: Ignoring strain-level identity

Using species names without adequate strain identification can weaken traceability and make it difficult to connect research findings with the commercial ingredient.

Better approach: Establish strain identity, documentation and appropriate quality specifications.

Mistake 5: Failing to assess the finished product's stability

Individual ingredients may meet their specifications before blending but behave differently in the finished formulation.

Better approach: Evaluate the complete formulation in its intended packaging and establish appropriate shelf-life specifications.

Mistake 6: Using evidence from unrelated formulations

A published study on one strain or combination may not substantiate a product with different ingredients, doses or intended uses.

Better approach: Assess how closely the available evidence matches the proposed commercial product.

Mistake 7: Making unsupported health claims

Scientific interest in the gut microbiome does not justify claims that a particular product prevents or treats a disease.

Better approach: Review the evidence, target market and permitted claim wording before finalising product labels and promotional material.

How Supplement Manufacturers Can Choose Between the Two

The decision should be based on the intended use, evidence, manufacturing capabilities and commercial requirements.

When a probiotic blend may be appropriate

A probiotic blend may be suitable when:

  • The product objective is based on selected probiotic strains.

  • The strains have relevant supporting evidence.

  • A prebiotic substrate is not necessary for the intended formulation.

  • The desired dosage form and viable-count requirements can be achieved.

  • The formulation can be manufactured and stored consistently.

A well-designed probiotic blend can provide a practical platform for a supplement brand seeking a defined combination of live microorganisms. Our guide to custom probiotic blends explains how to develop one step by step.

When a synbiotic blend may be appropriate

A synbiotic formulation may be appropriate when:

  • The product objective includes live microorganisms and a selectively utilized substrate.

  • A suitable substrate can be incorporated at an appropriate amount.

  • The substrate is compatible with the selected strains and dosage form.

  • The proposed complementary or synergistic approach has a scientific rationale.

  • The combined formulation can be shown to confer a relevant health benefit.

  • The finished product meets safety, stability and regulatory requirements.

The choice should not be based solely on the assumption that synbiotics are more advanced or more effective.

A practical decision framework

Development question

If yes

If no

Is the product objective clearly defined?

Establish evidence requirements

Refine the product concept

Are suitable probiotic strains available?

Evaluate identity, safety, potency and evidence

Screen alternative strains

Is a prebiotic substrate needed for the objective?

Evaluate suitable substrates

Consider a probiotic-only formulation

Is there evidence supporting the proposed combination?

Proceed to formulation development

Generate additional data

Can the finished product maintain required potency?

Confirm through stability studies

Reassess the formulation, process or packaging

Are the intended claims permitted in the target market?

Finalise compliant product communication

Revise claims or seek regulatory guidance

This process helps manufacturers avoid unnecessary formulation complexity and focus development resources on products with a clear scientific and commercial rationale.

The Future of Probiotic and Synbiotic Formulation

Research into the human microbiome continues to influence the development of probiotic and synbiotic products.

Emerging areas include more precise strain selection, improved delivery systems, better characterisation of microorganism–substrate interactions and analytical methods for investigating microbial activity.

More precise strain–substrate selection

Rather than combining ingredients based only on their general category, researchers can investigate how specific strains interact with particular substrates.

This approach may help identify combinations with useful functional characteristics.

However, promising laboratory findings must still be evaluated under conditions relevant to the intended product and target population.

Improved delivery technologies

Microencapsulation and related delivery technologies are being investigated to protect probiotic microorganisms from processing and storage stresses.

Depending on the formulation, these approaches may help manage exposure to moisture, oxygen, temperature or gastrointestinal conditions.

Research into encapsulation materials and synbiotic delivery systems illustrates the range of approaches being explored. Their suitability must be established for the actual product through appropriate stability and performance testing.

Integration of formulation science and clinical research

A stronger connection between formulation development and clinical research can help manufacturers determine which product characteristics are relevant to the intended health benefit.

This may involve evaluating the finished formulation rather than relying exclusively on evidence for individual ingredients.

For synergistic synbiotics, the research objective is particularly specific: the relevant microorganism–substrate relationship and the health benefit must both be demonstrated.

More transparent scientific communication

Clear distinctions among probiotic blends, complementary synbiotics and synergistic synbiotics can help buyers evaluate products more effectively.

Manufacturers that maintain reliable strain identification, quality specifications, stability data and scientific documentation make it easier for customers to assess formulation suitability.

The future of the category will depend not only on new ingredients but also on the quality of evidence supporting their use.

Develop Probiotic and Synbiotic Blends With Swiss Medicare Probiotics

Swiss Medicare Probiotics supplies bulk probiotic strains and probiotic blends for supplement and functional food brands, with formulation support for probiotic-only and probiotic-plus-prebiotic products. Contact our team to discuss your formulation objective, target market and documentation needs.

Related Reading

Frequently Asked Questions

1. What is the main difference between a probiotic blend and a synbiotic blend?

A probiotic blend combines multiple probiotic strains in a formulation. A synbiotic combines live microorganisms with selectively utilized substrates in a formulation that confers a health benefit. Synbiotics may be complementary or synergistic, depending on how their components are selected and intended to function.

Not necessarily. The effectiveness of either formulation depends on the strains, substrate, dose, intended use and supporting evidence. A well-designed probiotic blend may be suitable for one application, while a substantiated synbiotic may be preferable for another. There is no universal evidence that synbiotics are always superior.

Many commercial synbiotic supplements combine probiotic microorganisms with prebiotic ingredients. Under the ISAPP definition, however, a synbiotic is defined by the presence of live microorganisms and selectively utilized substrates that confer a health benefit. The requirements differ according to whether the formulation is complementary or synergistic.

No. Adding inulin does not automatically establish that the finished product qualifies as a scientifically substantiated synbiotic. The formulation must satisfy the relevant criteria for its intended category and demonstrate a health benefit. For a synergistic synbiotic, selective utilization of the substrate by the co-administered microorganism must also be demonstrated.

A complementary synbiotic combines a probiotic and a prebiotic that contribute to a health benefit without necessarily functioning cooperatively. A synergistic synbiotic is specifically designed so that the substrate is selectively utilized by the co-administered live microorganism or microorganisms.

Commonly investigated ingredients include inulin, fructooligosaccharides (FOS), galactooligosaccharides (GOS) and certain resistant starches. Their suitability depends on selective utilization, scientific evidence, dosage, gastrointestinal tolerance, ingredient compatibility and the requirements of the intended application.

Yes. A synbiotic can contain multiple probiotic strains alongside one or more suitable substrates. However, the manufacturer should evaluate strain compatibility, substrate utilization where relevant, viable-cell potency, stability and the evidence supporting the finished formulation.

Yes. Both formulation types can be developed for suitable dosage forms, including capsules and powder sachets. The final format depends on the viable dose, ingredient quantities, processing conditions, packaging requirements and stability of the finished product.

Yes. The stability programme should evaluate the complete formulation rather than relying solely on the stability of its individual ingredients. Relevant considerations include probiotic viability, moisture, packaging compatibility, substrate characteristics and shelf-life performance.

Quality assessment commonly includes strain identity, viable-cell count, microbiological purity, safety specifications and stability. Depending on the product, manufacturers may also evaluate moisture, water activity, physical characteristics and packaging integrity.

Synbiotic quality assessment includes appropriate probiotic tests, substrate specifications and relevant finished-product characteristics. Manufacturers should also maintain scientific documentation supporting the formulation's intended classification and health benefit.

Not necessarily. The number of strains does not independently determine efficacy. A single-strain product may be appropriate when supported by relevant evidence, while a multi-strain blend may be useful when the combination has a clear scientific rationale and suitable supporting data.

Both types of formulation are investigated for digestive and gastrointestinal applications. However, the evidence varies by strain, substrate, formulation and intended outcome. Product descriptions should reflect the available evidence and applicable regulations rather than implying that every product provides the same benefits.

Manufacturers should review strain-specific evidence, substrate-utilization studies, safety information, formulation compatibility data, clinical studies and applicable regulatory requirements. The evidence should be relevant to the proposed product and target population.

ClinicalTrials.gov provides information about registered clinical studies, including their objectives, designs, recruitment status and, where available, results. Researchers can use it to identify ongoing or completed studies, but registration alone does not establish that a formulation is effective.

Buyers should consider requesting technical data sheets, certificates of analysis, strain identification records, viable-count specifications, relevant safety documentation, stability data, storage instructions and supporting scientific references. Additional documentation may be needed for regulatory assessment and market entry.

Potentially, yes. A manufacturer can investigate adding a suitable substrate to an existing probiotic formulation. However, the resulting product requires a new assessment of ingredient compatibility, stability, dosage, scientific substantiation and regulatory suitability. Simply adding a prebiotic does not establish that the product is a validated synbiotic.

The most important consideration is the scientific and technical suitability of the complete formulation for its intended use. This includes appropriate microorganisms, a suitable substrate, safety, evidence of health benefit, stability, quality control and regulatory compliance.

Scientific References

The numbered references correspond to the citations used throughout the article.

[1] Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology & Hepatology. 2020;17:687–701. PubMed | Nature | PubMed Central (free full text)

[2] Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11:506–514. PubMed | Nature

[3] Gibson GR, Hutkins R, Sanders ME, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology. 2017;14:491–502. PubMed | Nature

[4] Synbiotic formulation and delivery research: studies of synbiotic delivery systems, encapsulation materials and probiotic protection. ScienceDirect search (a research search page, not a single peer-reviewed article).

[5] Zhou S, et al. Comparative efficacy and tolerability of probiotic, prebiotic, and synbiotic formulations for adult patients with mild-moderate ulcerative colitis in an adjunctive therapy: A network meta-analysis. Clinical Nutrition. 2024;43(1):20–30. PubMed | ScienceDirect

[6] European Food Safety Authority (EFSA). Health claim application procedure. EFSA health-claim procedure | European Commission EU Register of Health Claims

Additional resource: ClinicalTrials.gov, a public registry of clinical studies, including trials of probiotic, prebiotic and synbiotic formulations. Search synbiotic clinical trials

Scientific note: These sources support the scientific concepts discussed in the article, but they do not establish the efficacy of every probiotic or synbiotic formulation. Individual findings should be interpreted according to the strains, substrates, doses, populations and outcomes investigated.

 
 
 

Comments


bottom of page